Incorporating Epicel (cultural epidermal autografts) into practice for a variety of patientsTuesday, October 11, 2022
Speaker: Brett Hartman, DO
Moderator: James G Boron, MD, FACS, FCCP, Vericel Corporation
Join us for a tailored program for fellows and new users overviewing Epicel, including planning methodology, treatment algorithm, and case studies. Featuring Brett Hartman, DO, Director for Riley Hospital for Children Speedway Burn Unit and Richard M. Fairbanks Burn Center at Eskenazi Health and Assistant Professor of Plastic Surgery Burn Surgery Fellowship Director for Indiana, University School of Medicine Division of Plastic Surgery.
Q&A session with Dr. Hartman will follow.
Please see Epicel full Important Safety Information, Instructions for Use and Patient Information for more information.
Epicel (cultured epidermal autografts) is authorized for use in adult and pediatric patients who have deep dermal or full thickness burns comprising a total body surface area greater than or equal to 30%. It may be used in conjunction with split-thickness autografts, or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns. The effectiveness of the device for this use has not been demonstrated.
Important Safety Information
Epicel is contraindicated in patients with a history of anaphylaxis following exposure to vancomycin, amikacin, and amphotericin, as trace quantities of these anti-infective agents may remain in the Epicel autograft. Epicel should not be used in patients with known sensitivities to materials of bovine or murine origin. It is contraindicated for use on clinically infected wounds.